Octávio Costa
Nessuna posizione attualmente
Storia della carriera di Octávio Costa
Precedenti posizioni note di Octávio Costa
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Direttore Tecnico/Scientifico/R&S | - | - |
| MONOPAR THERAPEUTICS INC. | Direttore Tecnico/Scientifico/R&S | 12/07/2021 | - |
Formazione di Octávio Costa
| Pontifícia Universidade Católica de São Paulo | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
| Brasile | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 2 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MONOPAR THERAPEUTICS INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
- Borsa valori
- Insiders
- Octávio Costa
- Esperienza
